Business Wire

PHILIP-MORRIS-INTL

21.1.2020 10:05:13 CET | Business Wire | Press release

Share
Majority of People Want Governments to Do More to Reduce Smoking Rates, According to a New Global Survey From PMI

As it continues to advocate for greater transparency, objective examination of the science and open debate in creating the right regulation for smoke-free alternatives, Philip Morris International Inc. (PMI) (NYSE:PM) today released a new white paper titled, “Unsmoke Your Mind: Pragmatic Answers to Tough Questions for a Smoke-Free Future” at a press conference in Davos. Based on an independent survey—commissioned by PMI and conducted by Povaddo among 17,251 adults aged 21-74 across 14 countries—the paper examines public opinions of the regulatory, scientific and corporate landscape as PMI focuses on advancing smoke-free products to replace cigarettes as soon as possible.

The white paper shows a keen public appetite for open science and facts-driven policies regarding smoke-free alternatives to cigarettes. Nearly 9 in 10 respondents (87 percent) agreed that “when developing regulations, governments, regulators and public health bodies should consider the current science relating to e-cigarettes and heat-not-burn tobacco products.” Further underscoring support for scientific substantiation in this category is the fact that 89 percent of respondents agreed that “before introducing e-cigarettes and heat-not-burn tobacco products to consumers, manufacturers must conduct robust scientific assessments on their products.”

“Smoke-free alternatives offer a commonsense approach to public health,” said Jacek Olczak, chief operating officer at PMI. “In a time when trust in governments and organizations is at an all-time low, it is essential to base decision-making on science and facts. For PMI, this research reinforces the importance of transparency in sharing the science behind our smoke-free products, making it open for all, be that governments, regulators, scientists, academics or the general public.”

While it is best to quit tobacco and nicotine altogether or never to start using them, the reality is that there are millions of adult smokers who would otherwise continue smoking in the absence of a better alternative. Science and technology have now created these better alternatives, and these men and women should have access to them. Denying them access to these science-based better products means they will continue to smoke.

As smoke-free alternatives are increasingly in the headlines, the Unsmoke Your Mind white paper explores challenging questions the public has about the role of these products today, specifically addressing the following:

  • We & Me: Do societies at large really care about smokers?
  • Science Illuminates, Science Blinds: Do consumers take scientific evidence seriously or do they disregard “science” as just another marketing trick?
  • The Age of Mistrust: How does (mis)trust affect attitudes toward smoke-free alternatives?
  • The Promise and the Threat of What’s New: How can we be confident innovations will be better than what they replace?
  • Big Isn’t Always Bad: Are there any serious alternatives to “big” in a world of 7.8 billion people?

To read the “Unsmoke Your Mind: Pragmatic Answers to Tough Questions for a Smoke-Free World” paper, visit www.pmi.com/UYMwhitepaper .

Survey Methodology
PMI commissioned Povaddo LLC to conduct an online survey among 17,251 men and women aged 21-74 in 14 countries: Argentina, Australia, Brazil, Germany, Hong Kong, Israel, Italy, Japan, Mexico, the Netherlands, Norway, Russia, the United Kingdom and the United States. The survey was fielded from December 4-19, 2019 in respondents’ native languages. The study carries an overall margin of error of +/- 0.75% at the 95% confidence interval.

Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. PMI ships a version of its smoke-free devices and consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release

Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe

SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release

Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye